Abevmy follows the launch of the company’s two oncology biosimilars in Canada, Ogivri (bTrastuzumab) in 2019 – the first Trastuzumab approved in the country – and Fulphila (bPegfilgrastim), which was launched in 2020
With the approval from the Central Drugs Standard Control Organisation (CDSCO), Jardiance is now the first approved therapy to improve outcomes for the full spectrum of heart failure regardless of ejection fraction
The vaccine was found to have 64% efficacy against symptomatic disease and 92% against severe Covid-19
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
This cost-effective tool will be of immense benefit to other high burden countries as well.
As part of large-scale clinical studies prior to market introduction, the AI software has now gone into clinical test with patients, so-called first-in-human applications
Children 5 through 11 years of age are now authorized to receive a booster dose at least five months after the second dose of the two-dose primary series
The curriculum has been curated for General Physicians working in Clinikk
Globally, cervical cancer is the fourth most common cancer among women, with approximately 30,447 new cases diagnosed in Europe in 2020
The latest certification endorses product for cold chain monitoring across 194 WHO member countries
Subscribe To Our Newsletter & Stay Updated
